Skip to main content

Table 1 Contingency tables for primary outcome completeness and consistency on evidence source level

From: Completeness and consistency of primary outcome reporting in COVID-19 publications in the early pandemic phase: a descriptive study

 

registry entries ( n  = 87)

preprints ( n  = 53)

journal articles ( n  = 63)

completeness

n0

all POs completely defined

n (%)

 ≥ 1 PO

incompletely defined

n (%)

no PO specified

n (%)

n0

all POs completely defined

n (%)

 ≥ 1 PO

incompletely defined

n (%)

no PO specified

n (%)

n0

all POs completely defined

n (%)

 ≥ 1 PO

incompletely defined

n (%)

no PO specified

n (%)

total

 

87

47 (54)

40 (46)

0 (0)

53

31 (58)

9 (17)

13 (25)

63

44 (70)

11 (17)

8 (13)

registration time point

retrosp.

53

25 (47)

28 (53)

0 (0)

32

20 (63)

5 (16)

7 (22)

39

27 (69)

6 (15)

6 (15)

prosp.

25

13 (52)

12 (48)

0 (0)

14

5 (36)

3 (21)

6 (43)

18

12 (67)

5 (28)

1 (6)

changes

9

9 (100)

0 (0)

0 (0)

7

6 (86)

1 (14)

0 (0)

6

5 (83)

0 (0)

1 (17)

study design

no RCT

35

19 (54)

16 (46)

0 (0)

26

11 (42)

4 (15)

11 (42)

21

10 (48)

5 (24)

6 (29)

RCT

52

28 (54)

24 (46)

0 (0)

27

20 (74)

5 (19)

2 (7)

42

34 (81)

6 (14)

2 (5)

pharma

yes

43

30 (70)

13 (30)

0 (0)

21

16 (76)

1 (5)

4 (19)

38

31 (82)

6 (16)

1 (3)

no

44

17 (39)

27 (61)

0 (0)

32

15 (47)

8 (25)

9 (28)

25

13 (52)

5 (20)

7 (28)

consistency

    

n0

all POs consistent

n (%)

 ≥ 1 PO inconsistent

n (%)

NAa

n (%)

n0

all POs consistent

n (%)

 ≥ 1 PO inconsistent

n (%)

NAa

n (%)

total

 

-

   

53

13 (25)

19 (36)

21 (40)

63

27 (43)

16 (25)

20 (32)

registration time point

retrosp.

-

   

33

7 (21)

11 (33)

15 (45)

39

15 (38)

12 (31)

12 (31)

prosp.

-

   

13

1 (8)

6 (46)

6 (46)

18

7 (39)

3 (17)

8 (44)

changes

-

   

7

5 (71)

2 (29)

0 (0)

6

5 (83)

1 (17)

0

study design

no RCT

-

   

25

4 (16)

13 (52)

8 (32)

21

6 (29)

7 (33)

8 (38)

RCT

-

   

28

9 (32)

6 (21)

13 (46)

42

21 (50)

9 (21)

12 (29)

pharma

yes

-

   

21

9 (43)

6 (29)

6 (29)

38

24 (63)

10 (26)

4 (11)

no

-

   

32

4 (13)

13 (41)

15 (47)

25

3 (12)

6 (24)

16 (64)

  1. Some numbers in columns do not add up to 100 because of rounding; PO Primary outcome, retrosp Retrospective, prosp Prospective, changes Prospective registration with retrospective changes, RCT Randomized controlled trial, pharma Involvement of pharmaceutical industry
  2. aregistered primary outcome incompletely defined, therefore not eligible for primary outcome consistency assessment
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us